Research peptide that acts on three metabolic receptors.
Purity 99.191% verified by Janoshik. Lot 317558.
USDT TRC-20Retatrutide is an investigational peptide: a molecule made of a chain of amino acids. In scientific papers it also appears as LY3437943.
It's studied for its effects on body weight and blood sugar control. Clinical trials are evaluating its efficacy and safety in people with obesity, overweight or type 2 diabetes.
Retatrutide activates the GIP, GLP-1 and glucagon receptors at the same time, which is why it's described as a triple agonist. These receptors receive signals that trigger responses in cells.
The analysis of the lot we're selling today, done by Janoshik, an independent lab.
Janoshik analyzed a sample from lot 317558. The result applies to that sample, not to every vial in the lot.
Reconstituting means mixing the powder in the vial with bacteriostatic water to get a solution that's ready to use. The peptide comes as a powder because it keeps better that way.
The same 6 steps as the video. Tap an image to see it full size.
Afterward: label the vial with the date you reconstituted it and keep it in the fridge (see Storage).
Once reconstituted, it needs cold and darkness.
This is a suggested progression, not a cycle you have to finish. You can stay on a dose for as long as you want. It follows the gradual increase used in the phase 2 trial (NEJM, 2023): going up slowly helps reduce nausea and stomach upset. If side effects show up, stay on your current dose longer before going up.
In the TRIUMPH-1 trial, some groups stayed at 4 mg and others reached 9 or 12 mg. This progression is a guide, not a goal you have to reach.
In the trials, higher doses produced more weight loss on average, and also more side effects. A higher dose doesn't guarantee a better result for you.
A few days without a change in weight don't mean your dose is too low.
In the trials: nausea, diarrhea, constipation and vomiting. How strong they are and how long they last varies from person to person.
Choose simple, low-fat meals. Don't lie down right after eating.
Add fiber gradually, drink enough water and stay active.
Eat slowly, in small portions, and stop when you feel full.
Drink water throughout the day. If you're nauseous, take small, frequent sips.
Write down the date of each dose, your appetite and any side effects. That way you can see how you're doing.
Tirzepatide activates the GIP and GLP-1 receptors. Retatrutide activates those two plus the glucagon receptor, which is why it's called a triple agonist. Acting on more receptors doesn't make it better for everyone.
In an analysis of a Lilly clinical trial, people who received retatrutide reported less hunger and less tendency to overeat, especially at the highest doses. Appetite doesn't go away completely.
In TRIUMPH-1, adults with obesity or overweight and no diabetes lost an average of 17.6% to 25.0% of their body weight at 80 weeks, depending on the dose, versus 3.9% with placebo. These are results for Lilly's investigational drug, not for KAILAB vials.
In Quality, on this same page, you can open the report for the strength and lot we sell.
Every peptide vial comes with one 3 mL vial of bacteriostatic water, plus alcohol wipes; the reconstitution guide is on this page. Shipping is free anywhere in Colombia, in discreet packaging.
If your payment is confirmed before 4 p.m. (Monday to Friday) or noon (Saturday), we ship it that same day. After that time, and on Sundays and Colombian holidays, we ship it the next business day. Bogotá time.
Cards, PSE, Nequi, Daviplata and Bancolombia through Wompi, or USDT on the TRC-20 network. You'll see every option at checkout.
Can't find your answer? Visit Help.
Clinical trials have seen reductions in body weight and blood sugar. Results vary with the dose, the population and how long the study ran.
Doses of 4, 9 and 12 mg once a week were compared with placebo in adults with obesity or overweight, without diabetes.
Average weight loss was 17.6% to 25.0%, depending on the dose, versus 3.9% with placebo. This analysis accounts for people who stopped treatment.
In adults with type 2 diabetes, doses of 4, 9 and 12 mg once a week were compared with placebo.
HbA1c, a measure of average blood sugar, fell by 1.7 to 1.9 percentage points, versus 0.8 with placebo. This analysis accounts for people who stopped treatment.
Last reviewed: Oct 21, 2026 · KAILAB team
Español0Retatrutide 10 mg
Research peptide that acts on three metabolic receptors.
Purity 99.191% verified by Janoshik. Lot 317558.USDT TRC-20For research use only. Not for human or veterinary use.
Retatrutide is an investigational peptide: a molecule made of a chain of amino acids. In scientific papers it also appears as LY3437943.
It's studied for its effects on body weight and blood sugar control. Clinical trials are evaluating its efficacy and safety in people with obesity, overweight or type 2 diabetes.
Retatrutide activates the GIP, GLP-1 and glucagon receptors at the same time, which is why it's described as a triple agonist. These receptors receive signals that trigger responses in cells.
This is a suggested progression, not a cycle you have to finish. You can stay on a dose for as long as you want. It follows the gradual increase used in the phase 2 trial (NEJM, 2023): going up slowly helps reduce nausea and stomach upset. If side effects show up, stay on your current dose longer before going up.
In the TRIUMPH-1 trial, some groups stayed at 4 mg and others reached 9 or 12 mg. This progression is a guide, not a goal you have to reach.
In the trials, higher doses produced more weight loss on average, and also more side effects. A higher dose doesn't guarantee a better result for you.
A few days without a change in weight don't mean your dose is too low.
In the trials: nausea, diarrhea, constipation and vomiting. How strong they are and how long they last varies from person to person.
Choose simple, low-fat meals. Don't lie down right after eating.
Add fiber gradually, drink enough water and stay active.
Eat slowly, in small portions, and stop when you feel full.
Drink water throughout the day. If you're nauseous, take small, frequent sips.
Write down the date of each dose, your appetite and any side effects. That way you can see how you're doing.
Tirzepatide activates the GIP and GLP-1 receptors. Retatrutide activates those two plus the glucagon receptor, which is why it's called a triple agonist. Acting on more receptors doesn't make it better for everyone.
In an analysis of a Lilly clinical trial, people who received retatrutide reported less hunger and less tendency to overeat, especially at the highest doses. Appetite doesn't go away completely.
In TRIUMPH-1, adults with obesity or overweight and no diabetes lost an average of 17.6% to 25.0% of their body weight at 80 weeks, depending on the dose, versus 3.9% with placebo. These are results for Lilly's investigational drug, not for KAILAB vials.
In Quality, on this same page, you can open the report for the strength and lot we sell.
Every peptide vial comes with one 3 mL vial of bacteriostatic water, plus alcohol wipes; the reconstitution guide is on this page. Shipping is free anywhere in Colombia, in discreet packaging.
If your payment is confirmed before 4 p.m. (Monday to Friday) or noon (Saturday), we ship it that same day. After that time, and on Sundays and Colombian holidays, we ship it the next business day. Bogotá time.
Cards, PSE, Nequi, Daviplata and Bancolombia through Wompi, or USDT on the TRC-20 network. You'll see every option at checkout.
Clinical trials have seen reductions in body weight and blood sugar. Results vary with the dose, the population and how long the study ran.
Doses of 4, 9 and 12 mg once a week were compared with placebo in adults with obesity or overweight, without diabetes.
Average weight loss was 17.6% to 25.0%, depending on the dose, versus 3.9% with placebo. This analysis accounts for people who stopped treatment.
See the TRIUMPH-1 results · Lilly, May 2026 ↗In adults with type 2 diabetes, doses of 4, 9 and 12 mg once a week were compared with placebo.
HbA1c, a measure of average blood sugar, fell by 1.7 to 1.9 percentage points, versus 0.8 with placebo. This analysis accounts for people who stopped treatment.
See the TRANSCEND-T2D-1 results · Lilly, March 2026 ↗See the paper in The Lancet · June 2026 ↗Last reviewed: Oct 21, 2026 · KAILAB team
